|
1
|
Humbert M, Sitbon O, Chaouat A, Bertocchi
M, Habib G, Gressin V, Yaïci A, Weitzenblum E, Cordier JF, Chabot
F, et al: Survival in patients with idiopathic, familial and
anorexigen-associated pulmonary arterial hypertension in the modern
management era. Circulation. 122:156–163. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fukumoto Y and Shimokawa H: Recent
progress in the management of pulmonary hypertension. Circ J.
75:1801–1810. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Morrell NW, Adnot S, Archer SL, Dupuis J,
Jones PL, MacLean MR, McMurtry IF, Stenmark KR, Thistlethwaite PA,
Weissmann N, et al: Cellular and molecular basis of pulmonary
arterial hypertension. J Am Coll Cardiol. 54(Suppl 1): S20–S31.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shimokawa H and Rashid M: Development of
Rho-kinase inhibitors for cardiovascular medicine. Trends Pharmacol
Sci. 28:296–302. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Satoh K, Fukumoto Y and Shimokawa H:
Rho-kinase: Important new therapeutic target in cardiovascular
diseases. Am J Physiol Heart Circ Physiol. 301:H287–H296. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nakagawa O, Fujisawa K, Ishizaki T, Saito
Y, Nakao K and Narumiya S: ROCK-I and ROCK-II, two isoforms of
rho-associated coiled-coil forming protein serine/threonine kinase
in mice. FEBS Lett. 392:189–193. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chevrier V, Piel M, Collomb N, Saoudi Y,
Frank R, Paintrand M, Narumiya S, Bornens M and Job D: The
rho-associated protein kinase p160ROCK is required for centrosome
positioning. J Cell Biol. 157:807–817. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wei L, Roberts W, Wang L, Yamada M, Zhang
S, Zhao Z, Rivkees SA, Schwartz RJ and Imanaka-Yoshida K: Rho
kinases play an obligatory role in vertebrate embryonic
organogenesis. Development. 128:2953–2962. 2001.PubMed/NCBI
|
|
9
|
Shimizu Y, Thumkeo D, Keel J, Ishizaki T,
Oshima H, Oshima M, Noda Y, Matsumura F, Taketo MM and Narumiya S:
ROCK-I regulates closure of the eyelids and ventral body wall by
inducing assembly of actomyosin bundles. J Cell Biol. 168:941–953.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Thumkeo D, Keel J, Ishizaki T, Hirose M,
Nonomura K, Oshima H, Oshima M, Taketo MM and Narumiya S: Targeted
disruption of the mouse rho-associated kinase 2 gene results in
intrauterine growth retardation and fetal death. Mol Cell Biol.
23:5043–5055. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Medhora M, Chen Y, Gruenloh S, Harland D,
Bodiga S, Zielonka J, Gebremedhin D, Gao Y, Falck JR, Anjaiah S and
Jacobs ER: 20-HETE increases superoxide production and activates
NAPDH oxidase in pulmonary artery endothelial cells. Am J Physiol
Lung Cell Mol Physiol. 294:L902–L911. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ma J, Zhang L, Li S, Liu S, Ma C, Li W,
Falck JR, Manthati VL, Reddy DS, Medhora M, et al:
8,9-Epoxyeicosatrienoic acid analog protects pulmonary artery
smooth muscle cells from apoptosis via ROCK pathway. Exp Cell Res.
316:2340–2353. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔCt method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Budhiraja R, Tuder RM and Hassoun PM:
Endothelial dysfunction in pulmonary hypertension. Circulation.
109:159–165. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pidgeon GP, Tamosiuniene R, Chen G,
Leonard I, Belton O, Bradford A and Fitzgerald DJ: Intravascular
thrombosis after hypoxia-induced pulmonary hypertension: Regulation
by cyclooxygenase-2. Circulation. 110:2701–2707. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Abe K, Tawara S, Oi K, Hizume T, Uwatoku
T, Fukumoto Y, Kaibuchi K and Shimokawa H: Long-term inhibition of
Rho-kinase ameliorates hypoxia-induced pulmonary hypertension in
mice. J Cardiovasc Pharmacol. 48:280–285. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Abe K, Shimokawa H, Morikawa K, Uwatoku T,
Oi K, Matsumoto Y, Hattori T, Nakashima Y, Kaibuchi K, Sueishi K
and Takeshit A: Long-term treatment with a Rho-kinase inhibitor
improves monocrotaline-induced fatal pulmonary hypertension in
rats. Circ Res. 94:385–393. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Doe Z, Fukumoto Y, Takaki A, Tawara S,
Ohashi J, Nakano M, Tada T, Saji K, Sugimura K, Fujita H, et al:
Evidence for Rho-kinase activation in patients with pulmonary
arterial hypertension. Circ J. 73:1731–1739. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Oka M, Fagan KA, Jones PL and McMurtry IF:
Therapeutic potential of RhoA/Rho kinase inhibitors in pulmonary
hypertension. Br J Pharmacol. 155:444–454. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Katula KS, Wright KL, Paul H, Surman DR,
Nuckolls FJ, Smith JW, Ting JP, Yates J and Cogswell JP:
Cyclin-dependent kinase activation and S-phase induction of the
cyclin B1 gene are linked through the CCAAT elements. Cell Growth
Differ. 8:811–820. 1997.PubMed/NCBI
|
